“Far and away the best prize that life offers is the chance to work hard at work worth doing”

– Theodore Roosevelt


We are leveraging our Pro-XTEN technology to build a robust pipeline of immuno-oncology therapeutics

development pipeline graphic

development pipeline graphic


AMX-818 is a conditionally active, masked T cell engager targeting HER2, a receptor tyrosine kinase expressed on a wide variety of solid tumors including breast, gastric, non-small cell lung, and colorectal cancers. AMX-818 comprises a tandem scFv core with a HER2-binding domain targeting the same epitope as pertuzumab, and a proprietary low affinity CD3 binding domain, each masked by a protease-releasable XTEN® mask. AMX-818 is designed to overcome the on-target, off-tumor toxicity issues associated with existing TCEs by mitigating toxicity against healthy tissues that also express the target antigen.